Erasmus School of Health Policy & Management
External PhD candidate | Health Technology Assessment (HTA)
- zietse@eshpm.eur.nl
More information
Work
- Michiel Zietse, Jacky Hu, Esther R. van Staveren, Leontine E.A.M.M. Spierings, Agnes Jager, Birgit C.P. Koch, Ron H.J. Mathijssen, Roelof W.F. van Leeuwen & Frederick W. Thielen (2025) - Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study - Breast, 84 - doi: 10.1016/j.breast.2025.104573 - [link]
- Ruben Malmberg, Leni van Doorn, Juul M. Cox, Alaa Daloul, Halima Ettafahi, Esther Oomen-De Hoop, Michiel Zietse, Monique E.M.M. Bos, Birgit C.P. Koch & Roelof W.F. van Leeuwen (2024) - Effect of Switching the Histamine-1 Receptor Antagonist Clemastine to Cetirizine in Paclitaxel Premedication Regimens: The H1-Switch Study - JCO Oncology Practice, 20 (9), 1243-1251 - doi: 10.1200/OP.24.00110 - [link]
